Former Eli Lilly representative sues over Mounjaro marketing complaints
A former Eli Lilly sales representative filed a lawsuit alleging she was fired after complaining that the company promoted its diabetes drug for weight loss prior to approval.
FTMQ Health, written by our newsroom0 views

A former Eli Lilly sales representative has filed a lawsuit alleging she was fired after complaining about the improper promotion of the diabetes drug Mounjaro. STAT News and STAT reported that Jennifer Mansion, who was hired four years ago as a senior territory manager in Dallas, claimed the company promoted the drug for weight loss before receiving regulatory approval. [1][2]
According to STAT News, Mansion observed other Eli Lilly sales representatives promoting the diabetes medication as a treatment for obesity. She also contended that a physician praised Mounjaro as a weight loss option during a luncheon sponsored by the drugmaker. [1]
Mounjaro contains tirzepatide, a gastric inhibitory polypeptide analog and GLP-1 receptor agonist administered through subcutaneous injections. The United States Food and Drug Administration approved Mounjaro on May 13, 2022, to treat type 2 diabetes alongside diet and exercise. Approval followed the SURPASS clinical trial program, where the highest dose of 15 milligrams reduced HbA1c levels by up to 2.3 percent. Tirzepatide is also sold under the brand name Zepbound in the United States for weight loss and sleep apnea. [4][5]
Eli Lilly and Company was founded by Eli Lilly, an American Civil War veteran and chemist who commanded the 9th Indiana Infantry Regiment and served as a Union Army colonel before returning to pharmacy work. [3]
In short
- Jennifer Mansion filed a lawsuit alleging Eli Lilly fired her after she complained about off-label marketing of Mounjaro.
- The lawsuit claims sales representatives and a doctor at a Lilly-sponsored lunch promoted Mounjaro for weight loss before regulatory approval.
- Mounjaro was approved by the FDA on May 13, 2022, to treat type 2 diabetes in adults.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]STAT+: Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drugSTAT News, 7d ago (the report this story comes from)
- [2]Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drugSTAT, 7d ago
Background
- [3]Eli Lilly on Wikipedia
- [4]Tirzepatide on Wikipedia
- [5]Mounjaro on Grokipedia
- [6]American Diabetes Association releases review following convention ejections FTMQ Health, 25d ago
Our newsroom writes these reports with the help of software, from the 6 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Health
Earlier reports of ours on the same people and subjects.
- Monash Institute researchers target post menopause heart health with new grantTop Stories, 15d ago
- Four states sue Trump administration over Medicaid work requirementsTop Stories, 11d ago
- GLP1 weight loss drugs linked to nutrient shortages in exploratory studyTop Stories, 4h ago
- Alignment Healthcare sues federal regulators over 2027 Medicare Advantage ratingsHealth Care, 36d ago
- MPs call for NHS weight management overhaul following Mounjaro rolloutHealth Care, 26d ago
More in Top Stories
- United States updates federal health data privacy regulations for patient records4h ago
- Apple launches large study to evaluate health artificial intelligence app4h ago
- United States loses official measles elimination status following severe outbreak4h ago
- GLP1 weight loss drugs linked to nutrient shortages in exploratory study4h ago
- Large and small waist sizes linked to higher death risk4h ago
- UK government to end Palantir NHS England contract in 20291d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.